CD80 and neoplasm: Tumor cells, tumor infiltrating lymphocytes and tumor associated myeloid cells express inhibitory PD-L1/CTLA4 ligands to engage PD-1 receptors on cytotoxic T cells and CD80/86 receptors on myeloid cells, effectively blocking immune activation against the tumor cells.